Research Divisions

Multiple Sclerosis


Penn has a National Multiple Sclerosis Society recognized National MS Comprehensive Care Center in recognition of its clinical expertise and patient-centered multidisciplinary approach to caring for patients with multiple sclerosis.  Advanced diagnostic measures and therapies are available to optimize MS care.  The MS program offers consultation and continued care for all patients with suspected MS, newly diagnosed MS, relapsing remitting disease, chronic progressive MS and other forms of neuroinflammatory and demyelinating disease. 

Centers and Programs

  • Nationally recognized MS Comprehensive Care Center of Excellence
  • Infusion Clinic
  • FDO for fingolimod

Labs

  • Kolson Lab
    We hypothesized that cellular adaptive stress responses, which can be triggered by virus infection, are not only activated in HIV monocyte-derived macrophages (HIV/MDM) but also modify neurotoxin release and inflammatory cascades associated with neurodegeneration. We have developed an in vitro model of HIV neurotoxicity utilizing human HIV/MDM and primary rat cortical neurons. With this system, we have demonstrated that HIV infection of MDM results in the modulation of specific components of the antioxidant response and the integrated stress response (ISR).

Clinical Trials

The Penn MS Program is involved in and conducts a variety of clinical trials geared toward advancing and improving patient evaluation, new advanced imaging techniques, immunologic studies and experimental therapeutic trials.

MS research currently includes: Clinical trials evaluating new MS therapies, Advanced imaging studies and Vision studies.

Studies

JCV Urine- Dynamic Expression of JC Virus in the Urine and its Relationship to JCV Serostatus
(Berger) $241,500

NARCRMS- North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
(Berger)

PCORI- Discontinuation of DMTs
(Berger)

Vitamin D- A randomized controlled trial of vitamin D supplementation in multiple sclerosis
(Markowitz) $3,280.20 per patient

Roche PPMS- A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
(Markowitz) $6,500 per patient

BAF312- A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312
(Markowitz) $1,354,193.30

COMB157G2301- A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
(MarkowitzBudget pending 

OCTiMS- A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis
(Jacobs) $28,900

UCLA- A Double Blind, Placebo Controlled Trial of Estriol Treatment in Women with Multiple Sclerosis: Effect on Cognition
(Jacobs) $14,300 per patient

BG12- A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis
(Jacobs) $40,250 per patient

TEVA GA- Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated with Copaxone
(Pruitt) $4,910 per patient

ECU-NMO301- A randomized double blind placebo controlled trial to evaluate the safety and efficacy of eculizumab for NMO
(Williamson) $91,749.30 per patient

ECU-NMO 302- A phase III open label extension of ECU-NMO-301 for relapsing neuromyelitis (NMO)
(Williamson) $154,457 per patient 

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.